Product Details

Purity

≥ 90% as determined by SDS-PAGE.

Endotoxin

Less than 1.0 EU/ug as determined by LAL method.

Activity

Measured by its binding ability in a functional ELISA. Immobilized Anti-CLEC9A recombinant antibody (CSB-RA740922MA1HU) at 2 μg/mL can bind Human CLEC9A protein. The EC50 is 2.915-3.520 ng/mL.

Target Names

CLEC9A

Uniprot No.

Q6UXN8

Alternative Names

C-type lectin domain family 9 member A; CD370; CLEC9A; UNQ9341/PRO34046

Species

Homo sapiens (Human)

Source

Mammalian cell

Expression Region

57-241aa

Target Protein Sequence

KLLQVSTIAMQQQEKLIQQERALLNFTEWKRSCALQMKYCQAFMQNSLSSAHNSSPCPNNWIQNRESCYYVSEIWSIWHTSQENCLKEGSTLLQIESKEEMDFITGSLRKIKGSYDYWVGLSQDGHSGRWLWQDGSSPSPGLLPAERSQSANQVCGYVKSNSLLSSNCSTWKYFICEKYALRSSV

Mol. Weight

50.4 kDa

Protein Length

Partial

Tag Info

N-terminal hFc1-Avi-tagged

Form

Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Buffer

Lyophilized from a 0.2 μm filtered PBS, 6% Trehalose, pH 7.4

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.

Troubleshooting and FAQs

Protein FAQs

Storage Condition

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shelf Life

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.

Lead Time

3-7 business days

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Datasheet & COA

Please contact us to get it.

Description

CLEC9A, a C-type lectin receptor expressed on cross-presenting dendritic cells, recognizes exposed actin filaments from necrotic cells and directs antigen uptake for CD8+ T cell priming—a pathway central to anti-tumor immunity and vaccine design. This biotinylated construct spanning residues 57–241 captures the extracellular ligand-binding domain and demonstrates quantified binding activity in functional ELISA, with an EC50 of 2.915–3.520 ng/mL against an anti-CLEC9A antibody, providing a validated basis for ligand-binding assays, competitive inhibition screening, and therapeutic antibody epitope mapping. Mammalian expression supports native glycosylation and disulfide bond formation critical for C-type lectin fold integrity, while the N-terminal hFc1-Avi tag enables oriented immobilization in SPR and BLI platforms for affinity characterization and blocking antibody validation. Purity exceeding 90% by SDS-PAGE and endotoxin below 1.0 EU/μg align with standards expected in cell-based functional assays and antibody screening workflows targeting dendritic cell receptors.

Target Background

Function

Functions as an endocytic receptor on a small subset of myeloid cells specialized for the uptake and processing of material from dead cells. Recognizes filamentous form of actin in association with particular actin-binding domains of cytoskeletal proteins, including spectrin, exposed when cell membranes are damaged, and mediate the cross-presentation of dead-cell associated antigens in a Syk-dependent manner.

Gene References into Functions

Clec9a is responsible for the antigen cross-presentation of dendritic cell subsets and may be a target of immunotherapy PMID: 27250027
findings demonstrate that CLEC9A is a specialized receptor that modulates the innate immune response when there is a mycobacterial infection PMID: 29065139
Data indicate that blood dendritic cell antigen 3 BDCA3(+) and C-type lectin domain family 9, member A CLEC9A(+) dendritic cells (DC) are of major importance in the induction of anti-viral and anti-tumor immunity. PMID: 24910448
Activated dendritic cell subsets expressing CD141/CLEA9A/CD1c, likely recruited into the tubulointerstitium, are positioned to play a role in the development of fibrosis and, thus, progression to chronic kidney disease. PMID: 24049150
study showsn that the DNGR-1 ligand is preserved from yeast to man and corresponds to the F-actin component of the cellular cytoskeleton; identification of F-actin as a DNGR-1 ligand suggests that cytoskeletal exposure is a universal sign of cell damage that can be targeted by the innate immune system to initiate immunity PMID: 22483800
High expression of DNGR-1 specifically and universally identifies a unique dendritic cells subset in mouse and humans. PMID: 22442345
propose that Clec9A provides targeted recruitment of the adaptive immune system during infection and can also be utilized to enhance immune responses generated by vaccines. PMID: 22483802
Data show that CLEC9A is only expressed on immature BDCA3(+) myeloid dendritic cells (mDCs). PMID: 22234694
For production of cytotoxic T cells, transgenic DEC-205 and Clec9A, but not Clec12A, are effective targets for antibody-mediated delivery of antigens for vaccination, although only in the presence of adjuvants. PMID: 21677141
A population of human dendritic cells (DC) that expresses DNGR-1 (CLEC9A) and high levels of BDCA3 and resembles mouse CD8alpha+ DCs in phenotype and function, is characterized. PMID: 20479117
DC, NK lectin group receptor-1 (DNGR-1) is a C-type lectin of the NK cell receptor group PMID: 18497879
CLEC9A functions as an activation receptor PMID: 18408006
analysis of differences between mouse and human Clec9A PMID: 18669894
CLEC9A functions as a SYK-coupled C-type lectin receptor to mediate sensing of necrosis by the principal dendritic-cell subset involved in regulating cross-priming to cell-associated antigens PMID: 19219027
The paper cited (J Clin Invest. 2008 Jun;118(6):2098-110) is the first characterization of human and mouse CLEC9A (a.k.a DNGR-1) PMID: 18497879

Hide All

Subcellular Location

Membrane; Single-pass type II membrane protein.

Tissue Specificity

In peripheral blood highly restricted on the surface of BDCA31(+) dendritic cells and on a small subset of CD14(+) and CD16(-) monocytes.

Database Links

HGNC: 26705

OMIM: 612252

KEGG: hsa:283420

STRING: 9606.ENSP00000348074

UniGene: Hs.531189

Code	CSB-MP740922HU-B
Abbreviation	Recombinant Human CLEC9A protein, partial, Biotinylated (Active)
MSDS	MSDS Datasheet
Size	$166
	Order now
Image	(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Activity Measured by its binding ability in a functional ELISA. Immobilized Anti-CLEC9A recombinant antibody (CSB-RA740922MA1HU) at 2 μg/ml can bind Human CLEC9A protein. The EC₅₀ is 2.915-3.520 ng/mL. Biological Activity Assay
Have Questions?	Leave a Message or Start an on-line Chat

Recombinant Human C-type lectin domain family 9 member A (CLEC9A), partial, Biotinylated (Active)

Product Details

Related Products

Customer Reviews and Q&A

Target Background

×CloseMessage